Puneeth Iyengar on the Benefits of Hypofractionated Radiation Therapy in Lung Cancer

Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

The addition of toripalimab to perioperative chemotherapy led to a statistically significant improvement in event-free survival for patients with non–small cell lung cancer.

Radioligand therapy with 177Lu-PSMA-I&T elicited favorable PSA responses and a safety profile similar to PSMA-617.